Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | RAB9A | P51151 | 5/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5035614 | 0.76 | POLB (0.54) | TDP1SMN1; SMN2ALDH1A1RAB9AL3MBTL1 | |
| SCHEMBL27886037 | 0.74 | TDP1 (0.73) | TDP1SMN1; SMN2ALDH1A1RAB9AL3MBTL1 | |
| SCHEMBL2782641 | 0.74 | LMNA (0.55) | TDP1SMN1; SMN2ALDH1A1RAB9AL3MBTL1 | |
| SCHEMBL3963940 | 0.73 | F10 (0.52) | TDP1SMN1; SMN2ALDH1A1RAB9AL3MBTL1 | |
| SCHEMBL23933096 | 0.73 | TDP1 (1.00) | TDP1SMN1; SMN2ALDH1A1RAB9AL3MBTL1 | |
| SCHEMBL2188598 | 0.73 | TDP1 (0.71) | TDP1SMN1; SMN2ALDH1A1RAB9AL3MBTL1 | |
| SCHEMBL2944497 | 0.73 | TDP1 (0.71) | TDP1SMN1; SMN2ALDH1A1RAB9AL3MBTL1 | |
| SCHEMBL29883158 | 0.73 | TDP1 (0.71) | TDP1SMN1; SMN2ALDH1A1RAB9AL3MBTL1 | |
| SCHEMBL3963966 | 0.72 | F10 (0.62) | TDP1SMN1; SMN2ALDH1A1RAB9AL3MBTL1 | |
| SCHEMBL2952697 | 0.72 | TSHR (0.69) | TDP1SMN1; SMN2ALDH1A1RAB9AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1569927-A2 | IMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | Aventis Pharma Deutschland GmbH (DE) | 2005-09-07 | — | — | EP | claimed |
| EP-1479674-A1 | Imidiazole-derivatives as factor xa inhibitors | Aventis Pharma Deutschland GmbH (DE) | 2004-11-24 | — | — | EP | claimed |
| US-20040171604-A1 | Imidazole derivatives as factor Xa inhibitors | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-09-02 | — | — | US | claimed |
| WO-2004050636-A2 | IMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-06-17 | — | — | WO | claimed |
| EP-1426364-A1 | Imidazole-derivatives as factor Xa inhibitors | Aventis Pharma Deutschland GmbH (DE) | 2004-06-09 | — | — | EP | claimed |
| US-7358268-B2 | Imidazole derivatives as factor Xa inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-04-15 | — | — | US | disclosed |
| EP-1569927-A2 | IMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | Aventis Pharma Deutschland GmbH (DE) | 2005-09-07 | — | — | EP | disclosed |
| EP-1479674-A1 | Imidiazole-derivatives as factor xa inhibitors | Aventis Pharma Deutschland GmbH (DE) | 2004-11-24 | — | — | EP | disclosed |
| US-20040171604-A1 | Imidazole derivatives as factor Xa inhibitors | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-09-02 | — | — | US | disclosed |
| WO-2004050636-A2 | IMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-06-17 | — | — | WO | disclosed |
| EP-1426364-A1 | Imidazole-derivatives as factor Xa inhibitors | Aventis Pharma Deutschland GmbH (DE) | 2004-06-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171604-A1 | Imidazole derivatives as factor Xa inhibitors | TFPI, F11, TFPI2 | TDP1 520/4885SMN1; SMN2 3556/4885ALDH1A1 1152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.